[
  {
    "ts": "2026-01-31T05:12:00+00:00",
    "headline": "AbbVie’s US$100b Pledge Raises Questions On Value, Margins And Debt",
    "summary": "AbbVie (NYSE:ABBV) has entered a voluntary agreement with the U.S. government to commit US$100b to U.S. research and development and capital investments over the next decade. The company is also launching a three year effort focused on lowering drug prices while expanding U.S. manufacturing and direct to patient care access. AbbVie is a large U.S. based pharmaceutical company with a portfolio that spans immunology, oncology and other therapeutic areas. The new commitment sits against a...",
    "url": "https://finance.yahoo.com/news/abbvie-us-100b-pledge-raises-051200576.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "5c13cd7e-e932-3cbf-8e45-5fa24846895f",
      "content": {
        "id": "5c13cd7e-e932-3cbf-8e45-5fa24846895f",
        "contentType": "STORY",
        "title": "AbbVie’s US$100b Pledge Raises Questions On Value, Margins And Debt",
        "description": "",
        "summary": "AbbVie (NYSE:ABBV) has entered a voluntary agreement with the U.S. government to commit US$100b to U.S. research and development and capital investments over the next decade. The company is also launching a three year effort focused on lowering drug prices while expanding U.S. manufacturing and direct to patient care access. AbbVie is a large U.S. based pharmaceutical company with a portfolio that spans immunology, oncology and other therapeutic areas. The new commitment sits against a...",
        "pubDate": "2026-01-31T05:12:00Z",
        "displayTime": "2026-01-31T05:12:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/4451284b0632c6e74466a63400764edd",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/cbaG7tZ9A8mqrilci3AeIQ--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/4451284b0632c6e74466a63400764edd.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/1OA9tdPdimVe1Dv1fa4MAQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/4451284b0632c6e74466a63400764edd.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/abbvie-us-100b-pledge-raises-051200576.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/abbvie-us-100b-pledge-raises-051200576.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ABBV"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-31T13:31:10+00:00",
    "headline": "Citi Sees a More Supportive Backdrop Forming for AbbVie (ABBV) and Biopharma",
    "summary": "AbbVie Inc. (NYSE:ABBV) is included among the 12 Best Stocks to Buy for the Long Term. On January 27, Citi modestly cut its price target on AbbVie Inc. (NYSE:ABBV) to $230 from $235 while leaving its Neutral rating unchanged. The adjustment was part of the firm’s broader Q4 review of the biopharma space. In its […]",
    "url": "https://finance.yahoo.com/news/citi-sees-more-supportive-backdrop-133110820.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "5ecd5000-255e-315e-a9e8-1c0d012b5d51",
      "content": {
        "id": "5ecd5000-255e-315e-a9e8-1c0d012b5d51",
        "contentType": "STORY",
        "title": "Citi Sees a More Supportive Backdrop Forming for AbbVie (ABBV) and Biopharma",
        "description": "",
        "summary": "AbbVie Inc. (NYSE:ABBV) is included among the 12 Best Stocks to Buy for the Long Term. On January 27, Citi modestly cut its price target on AbbVie Inc. (NYSE:ABBV) to $230 from $235 while leaving its Neutral rating unchanged. The adjustment was part of the firm’s broader Q4 review of the biopharma space. In its […]",
        "pubDate": "2026-01-31T13:31:10Z",
        "displayTime": "2026-01-31T13:31:10Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/c554ad8e2af773e2e2a8438bfe2291ee",
          "originalWidth": 1456,
          "originalHeight": 816,
          "caption": "Citi Sees a More Supportive Backdrop Forming for AbbVie (ABBV) and Biopharma",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/aXAa28AvezyRv056g_RUEg--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/c554ad8e2af773e2e2a8438bfe2291ee.cf.webp",
              "width": 1456,
              "height": 816,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/lzVMSqWRbEKelBHS4c050A--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/c554ad8e2af773e2e2a8438bfe2291ee.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/citi-sees-more-supportive-backdrop-133110820.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/citi-sees-more-supportive-backdrop-133110820.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ABBV"
            },
            {
              "symbol": "C"
            },
            {
              "symbol": "GMAB"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-31T14:35:53+00:00",
    "headline": "AbbVie Inc. (ABBV) Balances Analyst Caution with Pipeline Progress and Long-Term Growth",
    "summary": "AbbVie Inc. (NYSE:ABBV) is one of the best healthcare stocks to buy for 2026. On January 28, Goldman Sachs reaffirmed its Neutral rating and $223 price target on AbbVie Inc. (NYSE:ABBV) ahead of its Q4 2025 earnings and 2026 guidance release. The firm expects healthy growth, projecting $67.1 billion in revenue, $21.3 billion from Skyrizi, […]",
    "url": "https://finance.yahoo.com/news/abbvie-inc-abbv-balances-analyst-143553638.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "f98d680e-4b21-3c3d-8b42-92c55dc72a70",
      "content": {
        "id": "f98d680e-4b21-3c3d-8b42-92c55dc72a70",
        "contentType": "STORY",
        "title": "AbbVie Inc. (ABBV) Balances Analyst Caution with Pipeline Progress and Long-Term Growth",
        "description": "",
        "summary": "AbbVie Inc. (NYSE:ABBV) is one of the best healthcare stocks to buy for 2026. On January 28, Goldman Sachs reaffirmed its Neutral rating and $223 price target on AbbVie Inc. (NYSE:ABBV) ahead of its Q4 2025 earnings and 2026 guidance release. The firm expects healthy growth, projecting $67.1 billion in revenue, $21.3 billion from Skyrizi, […]",
        "pubDate": "2026-01-31T14:35:53Z",
        "displayTime": "2026-01-31T14:35:53Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/d286e8ba05d14927faa0783c78adbf83",
          "originalWidth": 250,
          "originalHeight": 200,
          "caption": "AbbVie Inc. (ABBV) Balances Analyst Caution with Pipeline Progress and Long-Term Growth",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/4CLlW5d8JqECr37AWqo_rA--~B/aD0yMDA7dz0yNTA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/d286e8ba05d14927faa0783c78adbf83.cf.webp",
              "width": 250,
              "height": 200,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/hvMeAsl9tUIOK2KJa22_lA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/d286e8ba05d14927faa0783c78adbf83.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/abbvie-inc-abbv-balances-analyst-143553638.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/abbvie-inc-abbv-balances-analyst-143553638.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ABBV"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]